Next Article in Journal
SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge
Previous Article in Journal
Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 15
Issue 6
10.3390/jcm15062258
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation

by
Eui Soo Han
,
Ho Joong Choi
*,
Jin Ha Chun
,
Jiyoung Kim
and
Young Kyoung You
Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2026, 15(6), 2258; https://doi.org/10.3390/jcm15062258
Submission received: 3 February 2026 / Revised: 10 March 2026 / Accepted: 12 March 2026 / Published: 16 March 2026
(This article belongs to the Topic Biomarkers of Disease: Discovery and Clinical Applications)
Browse Figures
Versions Notes

Abstract

Background/Objectives: Natural killer (NK) cells are essential mediators of innate immune defense and play a key role in tumor surveillance following liver transplantation (LT). Despite this, the prognostic relevance of pre-transplant NK cell activity in living donor LT (LDLT) has not been fully established. Methods: This retrospective analysis included 134 adult patients who underwent LDLT. NK cell activity was evaluated prior to transplantation using interferon-γ release assays and classified as low (<10 pg/mL) or high (≥10 pg/mL). Overall survival (OS) was assessed for all participants, whereas recurrence-free survival (RFS) was analyzed patients with HCC. Results: Patients classified as having high NK activity (≥10 pg/mL) experienced significantly better overall survival compared to those with low activity (log-rank p = 0.032). In the multivariate analysis, high NK activity showed a strong trend toward improved overall survival (HR, 0.52; 95% CI, 0.26–1.04; p = 0.063). Among recipients with HCC, high NK activity was associated with a markedly improved recurrence-free survival (log-rank p = 0.004). Multivariate Cox regression further established NK activity as an independent factor for tumor recurrence (HR, 0.27; 95% CI, 0.08–0.87; p = 0.028). Conclusions: Pre-transplant NK cell activity independently predicts both survival and recurrence following LDLT.

1. Introduction

Liver transplantation (LT) is the curative standard for end-stage liver disease and selected hepatocellular carcinoma (HCC) [1,2]. However, long-term survival is frequently compromised by tumor recurrence and immune-related complications, highlighting the need for reliable prognostic markers [3,4]. Among various factors, the recipient’s innate immune competence—particularly the functional status of natural killer (NK) cells—is critical for graft protection and tumor immunosurveillance [5,6,7].
NK cells act as the first line of defense, mediating direct cytotoxicity against malignant cells and orchestrating downstream adaptive immune responses [7,8,9]. While many studies have focused on the recovery of NK cell function after transplantation, the clinical relevance of a recipient’s baseline immune fitness prior to surgery remains poorly defined [10,11,12]. In the setting of Living Donor Liver Transplantation (LDLT), the predictable timing of the procedure makes such preoperative assessment particularly actionable, allowing for risk stratification before the initiation of intensive postoperative immunosuppression. This preoperative status is especially vital in LT recipients, as the initiation of intensive postoperative immunosuppression can abruptly alter the immune landscape, potentially masking or exacerbating underlying deficiencies [13,14].
Consequently, identifying patients with low preoperative NK activity could allow for more personalized risk stratification and adjusted management strategies. In this study, we investigated the prognostic significance of pre-transplant NK cell activity in living donor liver transplantation (LDLT). We hypothesized that higher baseline NK activity indicates superior immune competence, which independently predicts improved overall survival (OS) and reduced recurrence-free survival (RFS) in HCC patients.

2. Materials and Methods

This retrospective cohort study enrolled 134 consecutive adult patients who received living donor liver transplantation (LDLT) at Seoul St. Mary’s Hospital, The Catholic University of Korea, between January 2020 and December 2023. The recruitment period and the consecutive nature of patient enrollment have been explicitly stated to enhance transparency. All demographic and clinical variables were extracted from the institutional database and further validated through a comprehensive manual chart review to ensure data accuracy and minimize information bias. The cohort size represented all qualifying cases performed during this timeframe; a post hoc power calculation indicated approximately 82% power to detect a hazard ratio of 0.5 for overall survival with a two-sided α of 0.05. All transplant procedures were conducted following uniform surgical protocols by a single hepatobiliary surgical team. Exclusion criteria were age below 18 years and incomplete pre-transplant immune data, perioperative records, or follow-up documentation. Demographic and clinical variables for both recipients and donors, as well as intraoperative factors and post-transplant outcomes, were extracted from the institutional LT database and validated through manual chart review.
Pre-transplant peripheral blood samples were collected within two weeks prior to surgery to evaluate NK cell activity. NK cell function was measured using the NK Vue® interferon-γ release assay (ATGen, Seongnam, Republic of Korea), which quantifies IFN-γ secretion after stimulation of peripheral NK cells with Promoca® (a mixture of recombinant cytokines, including IL-12, IL-15, and IL-18, specifically designed to stimulate NK cells). Results were reported as IFN-γ concentration (pg/mL), and patients were categorized into low (<10 pg/mL) and high (≥10 pg/mL) NK activity groups, in alignment with both the manufacturer’s threshold and previous studies assessing immunologic competence in solid organ transplantation. This cutoff value has also been validated in earlier oncologic and transplant research [13].
The initial immunosuppression protocol did not differ between HCC patients and other benign diseases. Immunosuppressants included triple regimen of a calcineurin inhibitor (Cyclosporine or Tacrolimus), mycophenolate mofetil, and steroids. An interleukin-2 receptor blocker was administered on both the day of the operation and the fourth postoperative day. Steroids were withdrawn 1 month after surgery, and mycophenolate mofetil was withdrawn 6 months after surgery. Only a low dose of a single calcineurin inhibitor was administered after this period.
Overall survival (OS) was defined as the time from transplantation to death from any cause or last follow-up, whereas recurrence-free survival (RFS) was assessed exclusively among patients who underwent transplantation for hepatocellular carcinoma (HCC), defined as the interval from transplantation to radiologic evidence of recurrence or death, whichever occurred first. Patients alive without recurrence were censored at the date of their last surveillance imaging. Diagnosis of HCC recurrence was based on radiologic criteria using multiphasic CT or MRI following LI-RADS guidelines, with confirmation by multidisciplinary consensus when necessary.
Comparative analyses were conducted between low- and high-NK groups. Continuous variables were presented as mean ± standard deviation (SD) or median (interquartile range) where appropriate, and categorical variables as absolute counts and percentages. Differences between groups were evaluated using Student’s t-test or Mann–Whitney U-test for continuous data, and chi-square or Fisher’s exact test for categorical data. Survival analyses employed the Kaplan–Meier method, with differences between survival curves assessed using the log-rank test. Univariate Cox proportional hazards models were used to identify potential predictors of OS and RFS; variables with p < 0.30 were included in multivariate analyses via the enter method. Hazard ratios (HRs) and associated 95% confidence intervals (CIs) were calculated to estimate the relative risk for each variable. The proportional hazards assumption for the Cox models was verified using Schoenfeld residual tests. Multicollinearity among covariates was assessed using Variance Inflation Factors (VIF).
All statistical analyses were conducted using IBM SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA). A two-tailed p-value < 0.05 was considered to indicate statistical significance.

3. Results

A total of 134 adult patients who underwent living donor liver transplantation (LDLT) were included in this analysis. The median follow-up period was 41 months (range, 6–67 months). Based on pre-transplant NK cell activity, 56 patients (41.8%) were categorized as the low NK group (<10 pg/mL), while 78 patients (58.2%) composed the high NK group (≥10 pg/mL). Baseline clinical characteristics are detailed in Table 1. There were no statistically significant differences between groups regarding age, sex, body mass index (BMI), diabetes, or hypertension. Additionally, no difference was found in the etiology of liver disease, donor age, graft type, graft-to-recipient weight ratio (GRWR), or intraoperative parameters. Nevertheless, the high-NK group exhibited lower MELD scores (12.3 ± 7.1 vs. 18.9 ± 9.5, p < 0.001) and lower serum CRP levels (0.5 ± 1.1 vs. 1.8 ± 2.6, p < 0.001). The incidence of postoperative cytomegalovirus (CMV) infection was also significantly lower in the high-NK group (14.1% vs. 43.6%, p < 0.001).
Among the 70 patients who underwent transplantation due to hepatocellular carcinoma (HCC), subgroup characteristics are presented in Table 2. There were no significant differences between the NK groups in terms of age, sex, BMI, pre-transplant tumor markers (AFP, PIVKA-II), or tumor size. MELD and CRP values remained significantly lower in the high-NK group (p = 0.001 for both). Recurrence of HCC was observed in 39.1% of low-NK patients and 10.6% of high-NK patients (p = 0.013), and the frequency of CMV infection was notably higher in the low-NK group (43.5% vs. 6.4%, p < 0.001).
The Kaplan–Meier survival analysis revealed a significant difference in survival outcomes between the NK groups (Figure 1). The 1-, 3-, and 5-year overall survival rates were 94.6%, 82.5%, and 71.0% in the low-NK group compared with 98.7%, 92.3%, and 86.5% in the high-NK group (log-rank p = 0.032). The proportional hazards assumption was not violated for any variables in the OS model (global p = 0.412). In multivariate Cox regression analysis (Table 3), high NK activity (≥10 pg/mL) showed a trend toward improved overall survival, although it did not reach absolute statistical significance (HR 0.52, 95% CI 0.26–1.04, p = 0.063). None of the other covariates in the multivariate model, including MELD ≥ 25 (p = 0.959), presence of HCC (p = 0.586), or non-HBV etiology (p = 0.531), had a significant effect on survival.
Within the HCC subgroup, there was a substantial difference in recurrence-free survival (RFS) between NK groups (Figure 2). The 1-, 3-, and 5-year RFS rates were 88.6%, 69.7%, and 58.2%, respectively, in the low-NK group vs. 97.0%, 90.6%, and 84.3% in the high-NK group (log-rank p = 0.004). Similarly, the proportional hazards assumption for the RFS model was also satisfied (global p = 0.528). Multivariate Cox analysis (Table 4) identified high NK activity as an independent protective factor against recurrence (HR 0.27, 95% CI 0.08–0.87, p = 0.028); tumor size ≥ 5 cm significantly increased the risk of recurrence (HR 3.88, 95% CI 1.18–12.69, p = 0.025). Other analyzed variables, such as AFP ≥ 200 ng/mL and PIVKA-II ≥ 40 mAU/mL, were not significant in the multivariate model.

4. Discussion

In this single-center cohort of 134 living donor liver transplantation (LDLT) recipients, elevated pre-transplant NK cell activity (≥10 pg/mL by IFN-γ release) correlated with improved clinical outcomes. NK cells are crucial effectors within innate immunity, responsible for both viral elimination and tumor immune surveillance, and mounting evidence suggests that their functional status profoundly impacts outcomes following organ transplantation [5,7,15,16]. In the present cohort, individuals exhibiting high NK activity achieved significantly greater overall survival (OS) as demonstrated by Kaplan–Meier analysis (log-rank p = 0.032), While the multivariable Cox regression for OS yielded a p-value of 0.063 (HR 0.52, 95% CI 0.26–1.04), this substantial 48% reduction in mortality risk represents a strong clinical trend that supports the role of NK cells in mediating anti-tumor cytotoxicity and suppressing residual malignant cell populations. Crucially, these findings are consistent with prior studies that highlight the role of preoperative immune competence in graft protection and decreased mortality, suggesting that a robust innate immune system is a prerequisite for favorable long-term outcomes after transplantation [11,14,17].
Among the 70 patients transplanted for hepatocellular carcinoma (HCC), those with elevated NK cell activity demonstrated substantially reduced recurrence rates in both unadjusted (log-rank p = 0.004) and adjusted analyses (HR 0.27, 95% CI 0.08–0.87, p = 0.028), supporting the role of NK cells in mediating anti-tumor cytotoxicity and suppressing residual malignant cell populations [9,18,19]. The prognostic significance of preoperative NK activity likely stems from the effective clearance of circulating tumor cells (CTCs). High baseline NK activity provides a critical ‘first line of defense’ neutralizing CTCs and preventing the formation of micrometastatic lesions [20]. This early-stage immune clearance reduces the risk of long-term recurrence and mortality observed for years after the surgery [21]. Importantly, differences in prognosis between the groups became apparent early after transplantation and continued up to 5 years post-transplant. Furthermore, tumor size ≥ 5 cm independently predicted a higher risk of recurrence (HR 3.88, 95% CI 1.18–12.69, p = 0.025), underscoring the established importance of tumor burden in shaping oncologic outcomes after LT [3,22].
These results are consistent with existing biological principles. NK cells play a pivotal role in innate immune surveillance through cytotoxic mechanisms targeting malignant hepatocytes, such as perforin–granzyme exocytosis and Fas/FasL-mediated apoptosis, and they also secrete interferon-γ to potentiate downstream antitumor T cell responses [6,7,23]. Increased preoperative NK functional capacity may indicate a greater host immunological “reserve,” facilitating more complete elimination of residual tumor cells and improved early post-transplant immune control during periods of immunosuppression. Unlike earlier investigations that primarily evaluated NK cell restoration post-transplantation, our findings underscore the prognostic impact of baseline NK activity—prior to the initiation of immunosuppression—on long-term cancer and survival outcomes [5,9,24].
From a clinical perspective, a dichotomous, assay-based NK measure presents notable advantages. First, it is objective, expedient, and feasible to implement using peripheral blood samples, thereby supporting its routine application in preoperative assessment [25,26]. Second, its independent predictive value in multivariable analysis suggests that it provides incremental prognostic insight supplemental to standard clinical and oncologic variables [24,26]. Third, among HCC candidates, combining NK activity with established oncologic variables such as tumor size may enhance preoperative risk stratification: patients exhibiting both low NK activity and larger tumors could require more intensive surveillance protocols, increased imaging frequency, or individualized immunosuppression approaches following transplantation [3,22]. While our study was not intended to evaluate specific management strategies, these findings provide a rationale for developing NK-based pathways in peri-transplant decision-making.
Nonetheless, several limitations must be acknowledged. This study is subject to limitations inherent in its single-center, retrospective design, which may limit the generalizability of our findings to other clinical settings. While we attempted to reduce bias by using a consecutive patient cohort and standardized protocols, the relatively small sample size—particularly in the HCC subgroup (n = 70)—and the lack of external validation may affect the robustness of our results. Future prospective, multicenter studies are necessary to confirm the external validity of preoperative NK activity as a prognostic marker. Furthermore, this study did not include a healthy control group. While establishing a normal reference range is important, our focus was on internal risk stratification for prognostic purposes within the transplant candidate population, rather than defining a physiological baseline for the healthy population. Since all participants shared similar disease backgrounds, these relative differences remain clinically valid for preoperative screening.
Immunosuppression regimens (e.g., tacrolimus vs. mTOR inhibitors) were excluded from the analysis due to incomplete longitudinal data, but their possible influence on post-transplant immunity remains an important consideration. Postoperative immunosuppressants, such as tacrolimus and corticosteroids, are known to impair NK cell function by reducing interferon-γ production and cytotoxic potential [27,28]. In this context, a high preoperative NK activity likely reflects a robust baseline immune reserve that may afford superior residual tumor surveillance during the early post-transplant period, despite the suppressive effects of medication. Whether this benefit is primarily due to the baseline reserve or a faster recovery of immune function warrants further longitudinal investigation.
The number of events—particularly within the HCC subgroup—was relatively small, which can lead to wider confidence intervals and limit the ability to detect subtle associations. Dichotomizing continuous variables, such as NK activity, may reduce the fidelity of the data and obscure underlying non-linear associations. Nevertheless, we utilized the pre-specified 10 pg/mL cutoff—the validated clinical reference value for the NK Vue® assay—to ensure our findings are practical and easily reproducible for preoperative risk stratification in clinical practice. While conducting sensitivity analyses with continuous NK values or alternative cut-points might yield additional insights, maintaining this standardized threshold aligns with established oncologic research and facilitates direct clinical application by providing a clear objective criterion for surgeons. NK activity was assessed at only a single preoperative time point, and longitudinal changes before and after transplantation were not evaluated, preventing assessment of dynamic immunologic alterations or mediation (e.g., whether early post-LT immunity underlies the observed associations). Furthermore, certain pathological risk features, including microvascular invasion and detailed explant characteristics, were not incorporated into the model, which could enhance recurrence risk prediction when available.
Future research should prospectively validate these results in multicenter settings and investigate whether NK activity, analyzed as a continuous variable and integrated with tumor metrics (size, number, biomarkers), can inform a robust nomogram for individualized risk assessment. These results have the potential to optimize peri-transplant immune monitoring strategies and facilitate the identification of patients eligible for targeted immunomodulatory interventions. Studies that incorporate serial NK measurements alongside immunosuppression data and patterns of infection could provide further insights into mechanisms and help determine optimal intervention periods. The question of whether preservation or enhancement of NK function before or shortly after LT leads to improved cancer outcomes warrants focused investigation. In this context, recent research has highlighted the potential for modulating the HCC immune microenvironment to improve clinical outcomes. For instance, Ginsenoside Rh1 has been demonstrated to regulate the tumor immune landscape via the glucocorticoid receptor, thereby enhancing the efficacy of systemic therapies [29]. Such strategies complement our findings by providing a mechanistic framework for how baseline immune status can be optimized to improve long-term prognosis.

5. Conclusions

Despite its limitations, this study has significance to evaluate the possibility that preoperative NK cell activity can be used as a selection criterion for LT recipients. In conclusion, pre-transplant NK cell activity serves as an independent predictor of both overall survival and recurrence in LDLT recipients. When considered alongside tumor size in HCC patients, NK activity provides distinct risk information—reflecting both host immune function and tumor burden—and may be a practical, preoperative biomarker to refine risk stratification and direct post-transplant management.

Author Contributions

Conceptualization, E.S.H. and H.J.C.; Methodology, E.S.H., J.H.C., and J.K.; Formal Analysis, E.S.H., J.H.C., and J.K.; Writing—Original Draft Preparation, E.S.H.; Writing—Review & Editing, H.J.C.; Supervision, Y.K.Y. and H.J.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Approval for this study was obtained from the Institutional Review Board of Seoul St. Mary’s Hospital, The Catholic University of Korea (IRB No. KC23RISI0230). The IRB waived the need for informed consent due to the retrospective design of the study, in accordance with the Declaration of Helsinki.

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

No new data were created, and some data are unavailable due to privacy or ethical restrictions.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AFPAlpha-fetoprotein
CIConfidence interval
DMDiabetes mellitus
HBVHepatitis B virus
HCCHepatocellular carcinoma
HTNHypertension
HRHazard ratio
MELDModel for End-stage Liver Disease
NKNatural killer
PIVKA-IIProtein induced by vitamin K absence or antagonist-II

References

  1. Adam, R.; Karam, V.; Cailliez, V.; Grady, J.G.O.; Mirza, D.; Cherqui, D.; Klempnauer, J.; Salizzoni, M.; Pratschke, J.; Jamieson, N.; et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl. Int. 2018, 31, 1293–1317. [Google Scholar] [CrossRef]
  2. Yao, F.Y.; Mehta, N.; Flemming, J.; Dodge, J.; Hameed, B.; Fix, O.; Hirose, R.; Fidelman, N.; Kerlan, R.K., Jr.; Roberts, J.P. Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria. Hepatology 2015, 61, 1968–1977. [Google Scholar] [CrossRef]
  3. Filgueira, N.A. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J. Hepatol. 2019, 11, 261–272. [Google Scholar] [CrossRef] [PubMed]
  4. Cui, S.; Cao, S.; Chen, Q.; He, Q.; Lang, R. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. Front. Immunol. 2023, 14, 1118053. [Google Scholar] [CrossRef]
  5. Harmon, C.; Sanchez-Fueyo, A.; O’Farrelly, C.; Houlihan, D.D. Natural Killer Cells and Liver Transplantation: Orchestrators of Rejection or Tolerance? Am. J. Transplant. 2016, 16, 751–757. [Google Scholar] [CrossRef]
  6. Sun, C.; Sun, H.Y.; Xiao, W.H.; Zhang, C.; Tian, Z.G. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol. Sin. 2015, 36, 1191–1199. [Google Scholar] [CrossRef]
  7. Vivier, E.; Raulet, D.H.; Moretta, A.; Caligiuri, M.A.; Zitvogel, L.; Lanier, L.L.; Yokoyama, W.M.; Ugolini, S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331, 44–49. [Google Scholar] [CrossRef] [PubMed]
  8. Abel, A.M.; Yang, C.; Thakar, M.S.; Malarkannan, S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front. Immunol. 2018, 9, 1869. [Google Scholar] [CrossRef]
  9. Morvan, M.G.; Lanier, L.L. NK cells and cancer: You can teach innate cells new tricks. Nat. Rev. Cancer 2016, 16, 7–19. [Google Scholar] [CrossRef]
  10. Shi, F.D.; Ljunggren, H.G.; La Cava, A.; Van Kaer, L. Organ-specific features of natural killer cells. Nat. Rev. Immunol. 2011, 11, 658–671. [Google Scholar] [CrossRef] [PubMed]
  11. Fernández-Ruiz, M.; López-Medrano, F.; Romo, E.M.; Allende, L.M.; Meneu, J.C.; Fundora-Suárez, Y.; San-Juan, R.; Lizasoain, M.; Paz-Artal, E.; Aguado, J.M. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation. Liver Transpl. 2009, 15, 1209–1216. [Google Scholar] [CrossRef]
  12. Gao, Z.C.; Wan, H.; Shan, G.Y.; Zhang, Y.X.; Sun, Z.J.; Shi, Y.P.; Li, H.J. The role of natural killer cells in the immune response after liver transplantation. Transplant. Rev. 2026, 40, 100986. [Google Scholar] [CrossRef] [PubMed]
  13. Di Maira, T.; Little, E.C.; Berenguer, M. Immunosuppression in liver transplant. Best Pract. Res. Clin. Gastroenterol. 2020, 46–47, 101681. [Google Scholar] [CrossRef] [PubMed]
  14. Lerut, J.; Sanchez-Fueyo, A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 2006, 6, 1774–1780. [Google Scholar] [CrossRef] [PubMed]
  15. Gill, R.G. NK cells: Elusive participants in transplantation immunity and tolerance. Curr. Opin. Immunol. 2010, 22, 649–654. [Google Scholar] [CrossRef][Green Version]
  16. Mantovani, S.; Oliviero, B.; Varchetta, S.; Mele, D.; Mondelli, M.U. Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. Cancers 2020, 12, 926. [Google Scholar] [CrossRef] [PubMed]
  17. Panayotova, G.G.; Simonishvili, S.; Jin, L.; Nguyen, D.T.; Graviss, E.A.; Qin, Y.; Xynogala, A.; Ayorinde, T.; Minze, L.J.; Lemenze, A.; et al. Development and Internal Validation of a Pretransplant Biomarker Panel for Mortality Prediction Following Liver Transplant. JAMA Surg. 2026. [Google Scholar] [CrossRef]
  18. Liu, S.; Galat, V.; Galat, Y.; Lee, Y.K.A.; Wainwright, D.; Wu, J. NK cell-based cancer immunotherapy: From basic biology to clinical development. J. Hematol. Oncol. 2021, 14, 7. [Google Scholar] [CrossRef]
  19. Greppi, M.; De Franco, F.; Obino, V.; Rebaudi, F.; Goda, R.; Frumento, D.; Vita, G.; Baronti, C.; Melaiu, O.; Bozzo, M.; et al. NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances. Immunol. Lett. 2024, 270, 106932. [Google Scholar] [CrossRef]
  20. Kondo, E.; Koda, K.; Takiguchi, N.; Oda, K.; Seike, K.; Ishizuka, M.; Miyazaki, M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig. Surg. 2003, 20, 445–451. [Google Scholar] [CrossRef]
  21. Gross, E.; Sunwoo, J.B.; Bui, J.D. Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J. 2013, 19, 483–489. [Google Scholar] [CrossRef] [PubMed]
  22. Mazzaferro, V.; Regalia, E.; Doci, R.; Andreola, S.; Pulvirenti, A.; Bozzetti, F.; Montalto, F.; Ammatuna, M.; Morabito, A.; Gennari, L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996, 334, 693–699. [Google Scholar] [CrossRef] [PubMed]
  23. Caligiuri, M.A. Human natural killer cells. Blood 2008, 112, 461–469. [Google Scholar] [CrossRef]
  24. Lee, H.A.; Goh, H.G.; Lee, Y.S.; Jung, Y.K.; Kim, J.H.; Yim, H.J.; Lee, M.G.; An, H.; Jeen, Y.T.; Yeon, J.E.; et al. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol. 2021, 21, 258. [Google Scholar] [CrossRef]
  25. Lee, S.B.; Cha, J.; Kim, I.K.; Yoon, J.C.; Lee, H.J.; Park, S.W.; Cho, S.; Youn, D.Y.; Lee, H.; Lee, C.H.; et al. A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem. Biophys. Res. Commun. 2014, 445, 584–590. [Google Scholar] [CrossRef]
  26. Xue, J.S.; Ding, Z.N.; Meng, G.X.; Yan, L.J.; Liu, H.; Li, H.C.; Yao, S.Y.; Tian, B.W.; Dong, Z.R.; Chen, Z.Q.; et al. The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front. Immunol. 2022, 13, 872353. [Google Scholar] [CrossRef]
  27. Morteau, O.; Blundell, S.; Chakera, A.; Bennett, S.; Christou, C.M.; Mason, P.D.; Cornall, R.J.; O’Callaghan, C.A. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS ONE 2010, 5, e13294. [Google Scholar] [CrossRef] [PubMed]
  28. Ohira, M.; Nishida, S.; Tryphonopoulos, P.; Ruiz, P.; Ohdan, H.; Tzakis, A.G. Impact of Steroids on Natural Killer Cells Against Cytotoxicity and Hepatitis C Virus Replication. Transplant. Proc. 2017, 49, 1160–1164. [Google Scholar] [CrossRef]
  29. Wang, X.H.; Fu, Y.L.; Xu, Y.N.; Zhang, P.C.; Zheng, T.X.; Ling, C.Q.; Feng, Y.L. Ginsenoside Rh1 regulates the immune microenvironment of hepatocellular carcinoma via the glucocorticoid receptor. J. Integr. Med. 2024, 22, 709–718. [Google Scholar] [CrossRef]
Jcm 15 02258 g001
Figure 1. Overall Survival Stratified by Pre-transplant NK Cell Activity. Kaplan–Meier analysis demonstrates a significant improvement in overall survival among patients with high NK activity (≥10 pg/mL) compared to those with low NK activity (<10 pg/mL) (log-rank p = 0.032). The number at risk is provided below the X-axis.
Figure 1. Overall Survival Stratified by Pre-transplant NK Cell Activity. Kaplan–Meier analysis demonstrates a significant improvement in overall survival among patients with high NK activity (≥10 pg/mL) compared to those with low NK activity (<10 pg/mL) (log-rank p = 0.032). The number at risk is provided below the X-axis.
Jcm 15 02258 g001
Jcm 15 02258 g002
Figure 2. Recurrence-free Survival in HCC Recipients Based on NK Cell Activity. High NK activity (≥10 pg/mL) correlated with better recurrence-free survival following liver transplantation (log-rank p = 0.004). The number at risk is provided below the X-axis.
Figure 2. Recurrence-free Survival in HCC Recipients Based on NK Cell Activity. High NK activity (≥10 pg/mL) correlated with better recurrence-free survival following liver transplantation (log-rank p = 0.004). The number at risk is provided below the X-axis.
Jcm 15 02258 g002
Table 1. Baseline and perioperative characteristics stratified by NK cell activity.
Table 1. Baseline and perioperative characteristics stratified by NK cell activity.
VariableNK Cell < 10 pg/mL
(n = 56)		NK Cell ≥ 10 pg/mL
(n = 78)		p-Value
Recipient Factors
   Age (years)54.0 ± 11.256.5 ± 7.90.136
   Sex, Male (%)37 (66.1%)57 (73.1%)0.495
   Etiology of disease 0.308
   HBV (%)31 (55.4%)46 (59.0%)
   HCV (%)1 (1.8%)3 (3.8%)
   Alcohol use (%)14 (25.0%)23 (29.5%)
   Other causes (%)10 (17.9%)6 (7.7%)
   BMI (kg/m2)24.3 ± 4.024.3 ± 4.20.922
   Diabetes mellitus (%)14 (25.0%)23 (29.5%)0.706
   Hypertension (%)16 (28.6%)24 (30.8%)0.934
   MELD score18.9 ± 9.512.3 ± 7.1<0.001
   Child–Pugh score8.6 ± 2.97.1 ± 2.4<0.001
   CRP (mg/dL)1.8 ± 2.60.5 ± 1.1<0.001
   eGFR (mL/min/1.73 m2)95.4 ± 40.492.9 ± 23.50.655
   HCC present (%)23 (41.1%)47 (60.3%)0.044
Donor or
operative characteristics
   GRWR1.2 ± 0.31.3 ± 1.20.474
   Duration of operation (min)426.9 ± 88.4442.0 ± 107.80.391
   PRC transfusion (units)9.6 ± 7.87.2 ± 8.00.082
   FFP transfusion (units)7.9 ± 6.36.2 ± 6.30.121
   Right liver graft (%)41 (73.2%)57 (73.1%)1.000
Post-LT clinical outcomes
   CMV infection rate (%)24 (43.6%)11 (14.1%)<0.001
Values are reported as mean ± SD or n (%). The Student’s t-test, chi-square test, or Fisher’s exact test was applied as appropriate.
Table 2. HCC subgroup analysis: recipient-related factors, tumor characteristics, and clinical outcomes by NK cell activity.
Table 2. HCC subgroup analysis: recipient-related factors, tumor characteristics, and clinical outcomes by NK cell activity.
VariableNK Cell < 10 pg/mL (HCC+, n = 23)NK Cell ≥ 10 pg/mL (HCC+, n = 47)p-Value
Recipient-related factors
   Age (years)60.7 ± 7.258.3 ± 6.50.170
   Sex, Male (%)22 (95.7%)40 (85.1%)0.257
   BMI (kg/m2)24.1 ± 3.624.8 ± 4.50.524
   Diabetes mellitus (%)6 (26.1%)13 (27.7%)1.000
   Hypertension (%)9 (39.1%)17 (36.2%)1.000
   MELD score14.7 ± 8.69.7 ± 3.70.001
   Child–Pugh score6.9 ± 2.56.0 ± 1.80.073
   CRP (mg/dL)2.0 ± 3.20.3 ± 0.60.001
   eGFR (mL/min/1.73 m2)87.4 ± 22.395.1 ± 13.90.080
Oncologic characteristics
   AFP (ng/mL)80.9 ± 182.368.0 ± 282.60.847
   PIVKA-II (mAU/mL)342.1 ± 509.1156.6 ± 833.60.373
   Tumor diameter (cm)3.7 ± 1.92.9 ± 2.00.181
Outcomes following LT
   CMV infection (%)10 (43.5%)3 (6.4%)<0.001
   HCC recurrence (%)9 (39.1%)5 (10.6%)0.013
Values are reported as mean ± SD or n (%). The Student’s t-test, chi-square test, or Fisher’s exact test was applied as appropriate.
Table 3. Univariate and Multivariate Analyses of Overall Survival.
Table 3. Univariate and Multivariate Analyses of Overall Survival.
ParameterUnivariate HR (95% CI)Univariate
p-Value		Multivariate HR (95% CI)Multivariate
p-Value
NK ≥ 10 pg/mL (vs. <10)0.49 (0.25–0.96)0.0360.52 (0.33–1.04)0.063
Age ≥ 60 (vs. <60)1.40 (0.72–2.73)0.317––
Male (vs. Female)0.88 (0.43–1.79)0.715––
MELD ≥ 25 (vs. <25)1.54 (0.70–3.40)0.2801.02 (0.43–2.45)0.959
HCC present (vs. absent)0.63 (0.32–1.22)0.1700.80 (0.35–1.80)0.586
BMI ≤ 25 (vs. >25)1.19 (0.60–2.37)0.616––
DM or HTN (vs. none)0.81 (0.41–1.59)0.543––
Non-HBV etiology (vs. HBV)1.49 (0.77–2.88)0.2421.28 (0.59–2.77)0.531
eGFR < 60 (vs. ≥60)1.36 (0.48–3.87)0.559––
Values are reported as mean ± SD or n (%). The Student’s t-test, chi-square test, or Fisher’s exact test was applied as appropriate. Cox proportional hazards models were implemented. The multivariate model includes variables that demonstrated p < 0.30 in univariate analysis.
Table 4. Recurrence-free Survival Following Liver Transplantation in Patients with Hepatocellular Carcinoma.
Table 4. Recurrence-free Survival Following Liver Transplantation in Patients with Hepatocellular Carcinoma.
VariableUnivariate HR (95% CI)Univariate
p-Value		Multivariate HR (95% CI)Multivariate
p-Value
NK ≥ 10 pg/mL (vs. <10)0.23 (0.08–0.69)0.0090.27 (0.08–0.87)0.028
Tumor size ≥ 5 cm (vs. <5 cm)4.05 (1.26–12.99)0.0193.88 (1.18–12.69)0.025
AFP ≥ 200 ng/mL (vs. <200)2.18 (0.49–9.77)0.310––
PIVKA-II ≥ 40 mAU/mL
(vs. <40)		2.56 (0.90–7.30)0.0791.47 (0.47–4.61)0.508
Age ≥ 60 (vs. <60)1.01 (0.35–2.88)0.985––
MELD ≥ 25 (vs. <25)N/AN/A––
Univariate and multivariate Cox proportional hazards analyses were conducted. Variables with a p < 0.30 on univariate analysis and those deemed clinically relevant for NK activity were incorporated into the multivariate model. MELD ≥ 25 was excluded from the Cox regression analysis because no recurrence events occurred within this subgroup (n = 2).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Han, E.S.; Choi, H.J.; Chun, J.H.; Kim, J.; You, Y.K. Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation. J. Clin. Med. 2026, 15, 2258. https://doi.org/10.3390/jcm15062258

AMA Style

Han ES, Choi HJ, Chun JH, Kim J, You YK. Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation. Journal of Clinical Medicine. 2026; 15(6):2258. https://doi.org/10.3390/jcm15062258

Chicago/Turabian Style

Han, Eui Soo, Ho Joong Choi, Jin Ha Chun, Jiyoung Kim, and Young Kyoung You. 2026. "Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation" Journal of Clinical Medicine 15, no. 6: 2258. https://doi.org/10.3390/jcm15062258

APA Style

Han, E. S., Choi, H. J., Chun, J. H., Kim, J., & You, Y. K. (2026). Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation. Journal of Clinical Medicine, 15(6), 2258. https://doi.org/10.3390/jcm15062258

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop